The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon.
We treated 14 patients (4 malignant melanoma/10 renal carcinoma) with a combination of continuous infusion interleukin-2 (IL-2) and subcutaneous alpha-interferon. Variable concentrations of albumin were added to the infusion of IL-2. The toxicity of this regimen seems to be related to the percentage of albumin added to the IL-2 infusion. Partial responses were observed in 3 cases. Interestingly, 1 patient's response appeared dependent on the addition of human serum albumin. The mechanism of these effects is unknown, but the use of albumin with IL-2 should be carefully investigated in future studies.
Cassidy
J
J
CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, U.K.
Poole
C
C
Sharkie
E
E
Steward
W P
WP
Kaye
S B
SB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D012709:Serum Albumin / Q000008:administration & dosage*
D016898:Interferon-alpha; D007376:Interleukin-2; D012709:Serum Albumin